Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Identifieur interne : 000024 ( Canada/Analysis ); précédent : 000023; suivant : 000025Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Auteurs : Benjamin K A. Thomson [Canada] ; Thomas D. Nolin [États-Unis] ; Thomas J. Velenosi [Canada] ; David A. Feere [Canada] ; Michael J. Knauer [Canada] ; Linda J. Asher [Canada] ; Andrew A. House [Canada] ; Bradley L. Urquhart [Canada]Source :
- American journal of kidney diseases : the official journal of the National Kidney Foundation [ 1523-6838 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antiallergiques (pharmacocinétique), Anxiolytiques (pharmacocinétique), Cytochrome P-450 CYP3A (métabolisme), Dialyse péritonéale, Dialyse rénale, Femelle, Humains, Indice de gravité médicale, Insuffisance rénale chronique (), Midazolam (pharmacocinétique), Mâle, Rein (métabolisme), Sujet âgé, Sujet âgé de 80 ans ou plus, Terfénadine (analogues et dérivés), Terfénadine (pharmacocinétique).
- MESH :
- analogues et dérivés : Terfénadine.
- métabolisme : Cytochrome P-450 CYP3A, Rein.
- pharmacocinétique : Antiallergiques, Anxiolytiques, Midazolam, Terfénadine.
- Adulte, Adulte d'âge moyen, Dialyse péritonéale, Dialyse rénale, Femelle, Humains, Indice de gravité médicale, Insuffisance rénale chronique, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Anti-Allergic Agents (pharmacokinetics), Anti-Anxiety Agents (pharmacokinetics), Cytochrome P-450 CYP3A (metabolism), Female, Humans, Kidney (metabolism), Male, Midazolam (pharmacokinetics), Middle Aged, Peritoneal Dialysis, Renal Dialysis, Renal Insufficiency, Chronic (therapy), Severity of Illness Index, Terfenadine (analogs & derivatives), Terfenadine (pharmacokinetics).
- MESH :
- chemical , analogs & derivatives : Terfenadine.
- chemical , metabolism : Cytochrome P-450 CYP3A.
- chemical , pharmacokinetics : Anti-Allergic Agents, Anti-Anxiety Agents, Midazolam, Terfenadine.
- metabolism : Kidney.
- therapy : Renal Insufficiency, Chronic.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Peritoneal Dialysis, Renal Dialysis, Severity of Illness Index.
Abstract
Patients with kidney disease frequently experience adverse effects from medication exposure, even when drugs are cleared by nonrenal pathways. Although many studies suggest that nonrenal drug clearance is decreased in chronic kidney disease (CKD), there remains a paucity of in vivo studies in patients with varying degrees of decreased kidney function and those comparing the impact of dialysis modality (eg, hemodialysis [HD] and peritoneal dialysis [PD]).
DOI: 10.1053/j.ajkd.2014.09.015
PubMed: 25453994
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000390
- to stream PubMed, to step Curation: 000390
- to stream PubMed, to step Checkpoint: 000390
- to stream Ncbi, to step Merge: 004152
- to stream Ncbi, to step Curation: 004152
- to stream Ncbi, to step Checkpoint: 004152
- to stream Main, to step Merge: 000530
- to stream Main, to step Curation: 000530
- to stream Main, to step Exploration: 000530
- to stream Canada, to step Extraction: 000024
Links to Exploration step
pubmed:25453994Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.</title><author><name sortKey="Thomson, Benjamin K A" sort="Thomson, Benjamin K A" uniqKey="Thomson B" first="Benjamin K A" last="Thomson">Benjamin K A. Thomson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Nolin, Thomas D" sort="Nolin, Thomas D" uniqKey="Nolin T" first="Thomas D" last="Nolin">Thomas D. Nolin</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Velenosi, Thomas J" sort="Velenosi, Thomas J" uniqKey="Velenosi T" first="Thomas J" last="Velenosi">Thomas J. Velenosi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Feere, David A" sort="Feere, David A" uniqKey="Feere D" first="David A" last="Feere">David A. Feere</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Knauer, Michael J" sort="Knauer, Michael J" uniqKey="Knauer M" first="Michael J" last="Knauer">Michael J. Knauer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Asher, Linda J" sort="Asher, Linda J" uniqKey="Asher L" first="Linda J" last="Asher">Linda J. Asher</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="House, Andrew A" sort="House, Andrew A" uniqKey="House A" first="Andrew A" last="House">Andrew A. House</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Urquhart, Bradley L" sort="Urquhart, Bradley L" uniqKey="Urquhart B" first="Bradley L" last="Urquhart">Bradley L. Urquhart</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada; Department of Physiology and Pharmacology, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada. Electronic address: brad.urquhart@schulich.uwo.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario, Canada; Department of Physiology and Pharmacology, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25453994</idno><idno type="pmid">25453994</idno><idno type="doi">10.1053/j.ajkd.2014.09.015</idno><idno type="wicri:Area/PubMed/Corpus">000390</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000390</idno><idno type="wicri:Area/PubMed/Curation">000390</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000390</idno><idno type="wicri:Area/PubMed/Checkpoint">000390</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000390</idno><idno type="wicri:Area/Ncbi/Merge">004152</idno><idno type="wicri:Area/Ncbi/Curation">004152</idno><idno type="wicri:Area/Ncbi/Checkpoint">004152</idno><idno type="wicri:Area/Main/Merge">000530</idno><idno type="wicri:Area/Main/Curation">000530</idno><idno type="wicri:Area/Main/Exploration">000530</idno><idno type="wicri:Area/Canada/Extraction">000024</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.</title><author><name sortKey="Thomson, Benjamin K A" sort="Thomson, Benjamin K A" uniqKey="Thomson B" first="Benjamin K A" last="Thomson">Benjamin K A. Thomson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Nolin, Thomas D" sort="Nolin, Thomas D" uniqKey="Nolin T" first="Thomas D" last="Nolin">Thomas D. Nolin</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Velenosi, Thomas J" sort="Velenosi, Thomas J" uniqKey="Velenosi T" first="Thomas J" last="Velenosi">Thomas J. Velenosi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Feere, David A" sort="Feere, David A" uniqKey="Feere D" first="David A" last="Feere">David A. Feere</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Knauer, Michael J" sort="Knauer, Michael J" uniqKey="Knauer M" first="Michael J" last="Knauer">Michael J. Knauer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physiology and Pharmacology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Asher, Linda J" sort="Asher, Linda J" uniqKey="Asher L" first="Linda J" last="Asher">Linda J. Asher</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="House, Andrew A" sort="House, Andrew A" uniqKey="House A" first="Andrew A" last="House">Andrew A. House</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Urquhart, Bradley L" sort="Urquhart, Bradley L" uniqKey="Urquhart B" first="Bradley L" last="Urquhart">Bradley L. Urquhart</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Western University, London, Ontario, Canada; Department of Physiology and Pharmacology, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada. Electronic address: brad.urquhart@schulich.uwo.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Western University, London, Ontario, Canada; Department of Physiology and Pharmacology, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">American journal of kidney diseases : the official journal of the National Kidney Foundation</title><idno type="eISSN">1523-6838</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anti-Allergic Agents (pharmacokinetics)</term><term>Anti-Anxiety Agents (pharmacokinetics)</term><term>Cytochrome P-450 CYP3A (metabolism)</term><term>Female</term><term>Humans</term><term>Kidney (metabolism)</term><term>Male</term><term>Midazolam (pharmacokinetics)</term><term>Middle Aged</term><term>Peritoneal Dialysis</term><term>Renal Dialysis</term><term>Renal Insufficiency, Chronic (therapy)</term><term>Severity of Illness Index</term><term>Terfenadine (analogs & derivatives)</term><term>Terfenadine (pharmacokinetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiallergiques (pharmacocinétique)</term><term>Anxiolytiques (pharmacocinétique)</term><term>Cytochrome P-450 CYP3A (métabolisme)</term><term>Dialyse péritonéale</term><term>Dialyse rénale</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Insuffisance rénale chronique ()</term><term>Midazolam (pharmacocinétique)</term><term>Mâle</term><term>Rein (métabolisme)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Terfénadine (analogues et dérivés)</term><term>Terfénadine (pharmacocinétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Terfenadine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytochrome P-450 CYP3A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Anti-Allergic Agents</term><term>Anti-Anxiety Agents</term><term>Midazolam</term><term>Terfenadine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Terfénadine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytochrome P-450 CYP3A</term><term>Rein</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiallergiques</term><term>Anxiolytiques</term><term>Midazolam</term><term>Terfénadine</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Peritoneal Dialysis</term><term>Renal Dialysis</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Dialyse péritonéale</term><term>Dialyse rénale</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Insuffisance rénale chronique</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with kidney disease frequently experience adverse effects from medication exposure, even when drugs are cleared by nonrenal pathways. Although many studies suggest that nonrenal drug clearance is decreased in chronic kidney disease (CKD), there remains a paucity of in vivo studies in patients with varying degrees of decreased kidney function and those comparing the impact of dialysis modality (eg, hemodialysis [HD] and peritoneal dialysis [PD]).</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Thomson, Benjamin K A" sort="Thomson, Benjamin K A" uniqKey="Thomson B" first="Benjamin K A" last="Thomson">Benjamin K A. Thomson</name></noRegion><name sortKey="Asher, Linda J" sort="Asher, Linda J" uniqKey="Asher L" first="Linda J" last="Asher">Linda J. Asher</name><name sortKey="Feere, David A" sort="Feere, David A" uniqKey="Feere D" first="David A" last="Feere">David A. Feere</name><name sortKey="House, Andrew A" sort="House, Andrew A" uniqKey="House A" first="Andrew A" last="House">Andrew A. House</name><name sortKey="Knauer, Michael J" sort="Knauer, Michael J" uniqKey="Knauer M" first="Michael J" last="Knauer">Michael J. Knauer</name><name sortKey="Urquhart, Bradley L" sort="Urquhart, Bradley L" uniqKey="Urquhart B" first="Bradley L" last="Urquhart">Bradley L. Urquhart</name><name sortKey="Velenosi, Thomas J" sort="Velenosi, Thomas J" uniqKey="Velenosi T" first="Thomas J" last="Velenosi">Thomas J. Velenosi</name></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Nolin, Thomas D" sort="Nolin, Thomas D" uniqKey="Nolin T" first="Thomas D" last="Nolin">Thomas D. Nolin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Canada/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000024 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd -nk 000024 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Canada
|étape= Analysis
|type= RBID
|clé= pubmed:25453994
|texte= Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/RBID.i -Sk "pubmed:25453994" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |